Use of the Drospirenone-Only Contraceptive Pill in Adolescents with Endometriosis - 27/03/24

Doi : 10.1016/j.jpag.2024.02.003

Jessica Y. Shim, MD ^1,^2,^⁎ , Garrett Garbo, MD ³, Frances W. Grimstad, MD, MS ^1,², Ava Scatoni, BA ¹, Ellis P. Barrera, BA ⁴, Elizabeth R. Boskey, PhD, MPH, LICSW, MSW ¹
¹ Division of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts
² Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts
³ Department of Obstetrics, Gynecology, and Women's Heath, University of Minnesota, Minneapolis, Minnesota
⁴ Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts

^⁎Address correspondence to: Jessica Shim, MD, Division of Gynecology, Department of Surgery, Boston Children's Hospital, 333 Longwood Ave, LO-545 Boston, MA 02115; Phone (617) 355-7648Division of Gynecology, Department of SurgeryBoston Children's Hospital333 Longwood Ave, LO-545BostonMA02115

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Wednesday 27 March 2024

Abstract

Study Objective

To evaluate the efficacy and tolerability of a progestin-only pill containing 4 mg drospirenone (DRSP) as a hormonal therapy for the management of endometriosis-associated symptoms in adolescents and young adults.

Design

Retrospective cohort study.

Methods

A retrospective chart review was performed of all adolescents who were prescribed DRSP continuously (without placebo) for treatment of endometriosis at a single pediatric tertiary care center between 2019 and 2022. Electronic medical records were reviewed to obtain demographics and clinical characteristics of the patients. Measured outcomes included symptom resolution and medication discontinuation. The study was deemed IRB exempt.

Results

A total of 61 patients with endometriosis were prescribed DRSP during the study period, with a median age of 18.9 years (SD 2.3). The majority (97%) were laparoscopically confirmed to have endometriosis, and 85% had stage I disease. Before DRSP use, the most common medications trialed were norethindrone (57%) and norethindrone acetate (68%), and 56% had at least one medical contraindication to receiving estrogen-containing therapy. Of those with follow-up, 52% established an absence of bleeding/spotting, and 67% reported less pain at follow-up. One in 4 patients discontinued DRSP during the study period, most commonly due to breakthrough bleeding.